Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 1.00 |
| ▸ | JAK3 | P52333 | 18/20 | 1.00 |
| ▸ | JAK1 | P23458 | 17/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | OPA1 | O60313 | 1/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.62 |
| ▸ | STK16 | O75716 | 1/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | MARK3 | P27448 | 1/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | STAT5A | P42229 | 1/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620070 | 0.92 | JAK2 (1.00) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL16446332 | 0.92 | JAK2 (1.00) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL16446555 | 0.92 | JAK2 (1.00) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL16456466 | 0.91 | JAK2 (0.84) | JAK2JAK3JAK1 | |
| SCHEMBL16446787 | 0.90 | JAK2 (0.82) | JAK2JAK3JAK1 | |
| SCHEMBL16447886 | 0.89 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL2866901 | 0.89 | JAK2 (0.81) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL30051224 | 0.89 | JAK2 (0.81) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL2863402 | 0.87 | JAK2 (0.79) | JAK2JAK3JAK1BMPR1BPLK4 | |
| SCHEMBL30051760 | 0.87 | JAK2 (0.79) | JAK2JAK3JAK1BMPR1BPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | claimed |
| EP-3030561-B1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LTD (IN) | 2017-01-11 | — | — | EP | claimed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | claimed |
| EP-3030561-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | Cadila Healthcare Limited (IN) | 2016-06-15 | — | — | EP | claimed |
| WO-2015019365-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2015-02-12 | — | — | WO | claimed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| EP-3030561-B1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LTD (IN) | 2017-01-11 | — | — | EP | disclosed |
| EP-3030561-B1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LTD (IN) | 2017-01-11 | — | — | EP | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| EP-3030561-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | Cadila Healthcare Limited (IN) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019365-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.